Hepatobiliary MR contrast agents are useful to diagnose hepatocellular carcinoma in patients with Budd-Chiari syndrome.
AFP, alpha-fetoprotein
APHE, arterial phase hyperenhancement
BCS, Budd-Chiari syndrome
FNH, focal nodular hyperplasia-like
HBP, hepatobiliary phase
HCC
HCC, hepatocellular carcinoma
Imaging
LR, likelihood ratio
MRI
OATP, organic anionic transporting polypeptides
T1-w, T1-weighted imaging
TIPS, transjugular intrahepatic portosystemic shunt
WO, washout
liver cancer
non-invasive
tumor
vascular liver disease
Journal
JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
02
2020
accepted:
24
02
2020
entrez:
22
5
2020
pubmed:
22
5
2020
medline:
22
5
2020
Statut:
epublish
Résumé
Hepatobiliary phase (HBP) images can discriminate between benign and malignant liver lesions, but it is unclear if this approach can be used in patients with Budd-Chiari syndrome (BCS). Thus, we aimed to assess the diagnostic utility of HBP images in patients with BCS. This retrospective study included all patients admitted to our institution with a diagnosis of BCS and focal liver lesions on hepatobiliary contrast agent-enhanced MR imaging (HBCA-MRI) from 2000 to 2019. MR images were reviewed by 2 radiologists blinded to the diagnosis of the lesions. Patient and lesion characteristics were recorded, focusing on HBP imaging features. Twenty-six patients (mean 35 ± 11 years old [13-65]; 21 women [81%] 35 ± 12 years old [13-65]; 5 men [19%] 36 ± 10 years old [19-44]) with 99 benign liver lesions and 12 hepatocellular carcinomas (HCCs) were analyzed. Patients with HCC were significantly older than those with benign lesions (mean 50 ± 10 Most benign lesions showed homogeneous or peripheral hyperintensity on HBP images while all HCCs were homogeneously hypointense. HBP images are helpful to differentiate between benign lesions and HCCs and outperform other sequences. They should be systematically acquired for the characterization of focal lesions in patients with BCS. Hepatobiliary phase imaging is an approach that has recently been shown to discriminate between benign and malignant lesions in the liver. However, it was not known whether this imaging approach could be used effectively in patients with Budd-Chiari syndrome. Herein, we have shown that hepatobiliary phase imaging appears to be useful for differentiating between benign and malignant liver lesions in patients with Budd-Chiari syndrome.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Hepatobiliary phase (HBP) images can discriminate between benign and malignant liver lesions, but it is unclear if this approach can be used in patients with Budd-Chiari syndrome (BCS). Thus, we aimed to assess the diagnostic utility of HBP images in patients with BCS.
METHODS
METHODS
This retrospective study included all patients admitted to our institution with a diagnosis of BCS and focal liver lesions on hepatobiliary contrast agent-enhanced MR imaging (HBCA-MRI) from 2000 to 2019. MR images were reviewed by 2 radiologists blinded to the diagnosis of the lesions. Patient and lesion characteristics were recorded, focusing on HBP imaging features.
RESULTS
RESULTS
Twenty-six patients (mean 35 ± 11 years old [13-65]; 21 women [81%] 35 ± 12 years old [13-65]; 5 men [19%] 36 ± 10 years old [19-44]) with 99 benign liver lesions and 12 hepatocellular carcinomas (HCCs) were analyzed. Patients with HCC were significantly older than those with benign lesions (mean 50 ± 10
CONCLUSION
CONCLUSIONS
Most benign lesions showed homogeneous or peripheral hyperintensity on HBP images while all HCCs were homogeneously hypointense. HBP images are helpful to differentiate between benign lesions and HCCs and outperform other sequences. They should be systematically acquired for the characterization of focal lesions in patients with BCS.
LAY SUMMARY
BACKGROUND
Hepatobiliary phase imaging is an approach that has recently been shown to discriminate between benign and malignant lesions in the liver. However, it was not known whether this imaging approach could be used effectively in patients with Budd-Chiari syndrome. Herein, we have shown that hepatobiliary phase imaging appears to be useful for differentiating between benign and malignant liver lesions in patients with Budd-Chiari syndrome.
Identifiants
pubmed: 32435753
doi: 10.1016/j.jhepr.2020.100097
pii: S2589-5559(20)30031-8
pii: 100097
pmc: PMC7232085
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100097Informations de copyright
© 2020 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.
Références
Hepatol Int. 2018 Feb;12(Suppl 1):168-180
pubmed: 28685257
AJR Am J Roentgenol. 2002 Apr;178(4):869-75
pubmed: 11906865
AJR Am J Roentgenol. 2007 Feb;188(2):W168-76
pubmed: 17242224
Abdom Radiol (NY). 2018 Aug;43(8):1968-1977
pubmed: 29460040
Hepatobiliary Pancreat Dis Int. 2011 Aug;10(4):439-42
pubmed: 21813396
Radiology. 2016 Apr;279(1):118-27
pubmed: 26505921
Hepatology. 2018 Jan;67(1):358-380
pubmed: 28130846
Invest Radiol. 2008 Jul;43(7):504-11
pubmed: 18580333
AJR Am J Roentgenol. 2012 Jul;199(1):35-43
pubmed: 22733891
Gut. 2008 Jun;57(6):828-35
pubmed: 18218675
Eur Radiol. 2007 Aug;17(8):2071-8
pubmed: 17206425
Radiographics. 2009 May-Jun;29(3):669-81
pubmed: 19448109
Eur Radiol. 2016 Apr;26(4):921-31
pubmed: 26194455
Hepatology. 2003 Mar;37(3):510-9
pubmed: 12601347
Radiology. 2005 Jul;236(1):166-77
pubmed: 15955857
AJR Am J Roentgenol. 2002 Apr;178(4):877-83
pubmed: 11906867
Radiology. 1999 Feb;210(2):443-50
pubmed: 10207428
Case Rep Radiol. 2012;2012:685486
pubmed: 22606569
Jpn J Radiol. 2012 Jul;30(6):499-508
pubmed: 22618456
Radiology. 2015 Nov;277(2):413-23
pubmed: 26020440
J Hepatol. 2016 Jan;64(1):179-202
pubmed: 26516032
Korean J Radiol. 2010 Jul-Aug;11(4):433-40
pubmed: 20592927
J Hepatol. 2019 Jun;70(6):1123-1132
pubmed: 30654065
Radiology. 2012 Feb;262(2):520-9
pubmed: 22282184
Jpn J Radiol. 2011 Dec;29(10):739-43
pubmed: 22009428
Radiographics. 2002 Jul-Aug;22(4):847-62
pubmed: 12110714
Clin Mol Hepatol. 2016 Jun;22(2):199-211
pubmed: 27189732
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Chin Med J (Engl). 2013;126(19):3632-8
pubmed: 24112155
Eur J Gastroenterol Hepatol. 2004 Mar;16(3):319-24
pubmed: 15195897
Eur Radiol. 2019 Jun;29(6):3090-3099
pubmed: 30547205
Radiology. 2015 Oct;277(1):104-13
pubmed: 25985059
Eur J Radiol. 2019 Aug;117:15-25
pubmed: 31307641